Launch of the Third Biotech SPAC

JATT III Acquisition Corp. (JTTT) completed a $60 million Nasdaq IPO on August 26, 2026, issuing 6 million common shares at $10 per share. A target for acquisition has not yet been selected, and the merger deadline is 24 months following the completion of the public offering. The focus is on private life sciences companies utilizing Machine Learning, Computational Biology, and Structure-Based Drug Design. The investment scope extends beyond clinical assets to include platforms that enhance drug development productivity, distinguishing it from traditional single-pipeline SPACs.

Proven Execution Through Repeated Mergers

The first JATT Acquisition, led by CEO Someit Sidhu, completed a reverse merger with autoimmune disease company Zura Bio Ltd. (ZURA) in 2023. Zura's lead candidate, tibulizumab (ZB-106), is a clinical-stage dual-targeting antibody that simultaneously blocks interleukin-17A (IL-17A) and B-cell activating factor (BAFF) by combining the single-chain variable fragment of Taltz (ixekizumab) with tabalumab. TibuSHIELD, targeting pyoderma gangrenosum, and TibuSURE, targeting systemic sclerosis, have completed patient enrollment in Phase 2 trials, demonstrating JATT's ability to transform an initial platform into a mid-stage clinical company. However, JATT III shareholders are investing primarily in the management team's target selection and follow-on fundraising capabilities rather than specific assets.

Talawar Deal as a Capital-Raising Model

JATT II Acquisition Corp. (JATT) entered a merger agreement with Talawar Therapeutics Inc. in June 2026, and Access Biotechnology led a $225 million private investment in public equity (PIPE), with participation from Bain Capital Life Sciences and RA Capital Management. Including approximately $60 million in trust funds from JATT II, the merger company could have access to approximately $285 million in cash before redemptions. Talawar's preclinical dual-specific antibody TALA-125 simultaneously inhibits IL-13 and IL-18, aiming for Phase 1 clinical trials in Q1 2027 and proof-of-concept results in Phase 2b by late 2028. This sets a precedent for JATT III to adopt a similar financial structure combining SPAC public offering funds with biotech-focused PIPEs.

Competitive Drugs and Commercial Benchmarks

TALA-125 targets moderate-to-severe atopic dermatitis, where the standard biological therapies include Dupixent (dupilumab, an IL-4Rα inhibitor) and Adbry (tralokinumab-ldrm, an IL-13 inhibitor). The FDA approved Dupixent on March 28, 2017, and Adbry on December 27, 2021, while oral competitors include Cibinqo (abrocitinib, a JAK1 inhibitor) and Rinvoq (upadacitinib, a JAK1 inhibitor). Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) reported global net sales of Dupixent at $17.8 billion in 2025 across multiple indications, illustrating the commercial ceiling for immunology assets. Therefore, JATT III's enterprise value will depend on its ability to secure an acquisition target with differentiated targets, rapid clinical entry, and robust efficacy and safety data compared to standard-of-care treatments.